1. Pink Sheet
  2. >>Product Reviews

Boehringer Ingelheim Wins Interchangeable Biosimilar To Humira, Setting Benchmark For Switching Studies

 
• By Nielsen Hobbs

Cyltezo won’t be available until 2023 due to patent settlement with AbbVie. The second-ever interchangeable biosimilar approved by the US FDA also contains a first: published data from a switch trial.

sunrise over Greece
WITH AN INTERCHANGABLE DESIGNATION TO Abbvie’s HUMIRA, BOEHRINGER INGELHEIM’S CYLTEZO COULD HEARLD THE DAWN OF A NEW ERA FOR BIOSIMILARS IN THE US. • Source: Alamy

Boehringer Ingelheim GmbH’s Cyltezo has won an interchangeable biosimilar designation to AbbVie Inc.’s Humira from the US Food and Drug Administration. It’s an achievement that not only heralds the likely decline of earth’s mightiest franchise, but also paves the way for many more interchangeable products since it offers the first-ever published data on what a successful switch study looks like.

FDA granted Cyltezo (adalimumab-adbm) the interchangeable designation on 15 October, but the product’s commercial license won’t begin until 1 July...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.

US FDA Teases Disclosure Program, But Industry Has Seen This Before

 
• By Derrick Gingery

Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.

US FDA’s July AdComms: Pediatric Vaccine Safety, Blenrep’s Return, (Maybe) Capricor’s Cell Therapy

 
• By Sue Sutter

The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.